Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Certain drugs in this class may increase the likelihood of diabetes and hypertension, but cardiovascular risk factors can be managed.
Research on the links between tenofovir and other antiretrovirals, SARS-CoV-2 infection and COVID severity has produced mixed results.
Using two instead of three or four drugs could potentially lead to cost savings in the billions.
Only a small proportion of people who start treatment very early might be eligible for dolutegravir monotherapy.
Once-daily Biktarvy, long-acting injectable Cabenuva and two-drug combos containing dolutegravir can keep HIV in check for years.
Disruption of fat metabolism and altered gut microbiome may help explain weight changes associated with antiretroviral therapy.
People starting on integrase inhibitors were no more likely to have heart attacks, strokes or cardiovascular procedures.
HIV treatment has greatly improved over the past 36 years.
Switching from TAF to TDF may help people lose weight, but this must be balanced against the risk of kidney problems and bone loss.
The updated guidance says antiretroviral therapy should be started as soon as possible after diagnosis and outlines the latest options.
People who saw substantial CD4 T-cell gains during the first two years after diagnosis had better outcomes.
A high-quality trial should improve access to dolutegravir for children worldwide.
The long-acting injectable regimen suppressed HIV in more than 90% of study participants, including those with obesity.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.